Browse the latest research summaries in the field of regenerative medicine for spinal cord injury patients and caregivers.
Showing 441-450 of 2,298 results
Int. J. Mol. Sci., 2023 • September 8, 2023
The study investigated the therapeutic efficacy of immature chemical compound-induced neuronal-like (CiN) cells in a rat model of spinal cord injury (SCI). The transplantation of immature CiN cells re...
KEY FINDING: Locomotor recovery after SCI was partially improved in the immature CiN cell-transplanted group compared to the control group, as assessed by the BBB test and CatWalk analysis.
Int. J. Mol. Sci., 2023 • September 11, 2023
Spinal cord injury (SCI) is a significant health problem lacking fully effective treatments. Pharmacological and non-pharmacological strategies are being evaluated to improve neurological recovery. Th...
KEY FINDING: Various cell types like Schwann cells, olfactory ensheathing cells (OECs), and mesenchymal stem cells (BMSCs) can modulate inflammation after SCI, promoting neuroprotection and regeneration in animal models.
Front. Neurosci., 2023 • September 15, 2023
This study addresses the need for region-specific cell types in spinal cord injury research by developing standardized protocols to create hiPSC-derived spinal cord progenitors. The rapid induction ap...
KEY FINDING: The study successfully developed a rapid differentiation protocol, generating neural progenitors in 6 days and post-mitotic neurons in 20 days.
ibrain, 2023 • July 1, 2023
This review summarizes the therapeutic effects of UCBs on SCI, highlighting improvements in sensory and motor function, reduction of the injured area, axon regeneration, and modulation of inflammation...
KEY FINDING: Transplantation of UCBs and their derivatives has shown significant improvements in motor function in SCI animal models, as indicated by increased BBB scores and MEPs.
Int. J. Mol. Sci., 2023 • September 27, 2023
This study aimed to evaluate the therapeutic potential of intravenously administered Muse cells for subacute spinal cord injury (SCI) in a rat model. The clinical product “CL2020” containing Muse cell...
KEY FINDING: Intravenous administration of CL2020 containing Muse cells significantly improved hindlimb motor functions in rats with subacute spinal cord injury from 6 to 20 weeks after administration.
International Journal of Stem Cells, 2024 • November 29, 2023
This review summarizes the role of MSCs-Exos in SCI treatment, including regulating immune responses, promoting angiogenesis, activating autophagy and inhibiting apoptosis, regulating the permeability...
KEY FINDING: MSCs-Exos can reduce A1 neurotoxic astrocytes to improve the outcome of SCI. Wang et al. (88) found that intravenous administration of MSCs-Exos exerts anti-inflammatory and neuroprotective effects in a rat model of SCI
Brain Sci., 2023 • December 9, 2023
Stem cell therapy is considered a promising treatment for spinal cord injury (SCI), aiming to facilitate cellular and tissue regeneration and enhance functional recovery. Stem cells produce various gr...
KEY FINDING: Stem cells have shown potential in improving motor and sensory function in animal models of SCI, enhancing axon regeneration, reducing inflammation, and increasing tissue repair.
Regen Eng Transl Med, 2023 • September 1, 2023
The results of this study demonstrated successful injection and subsequent gelation of our iPN hydrogel formulation in vivo. PLGA encapsulation may be a promising avenue for combining iPN with pro-reg...
KEY FINDING: Gelation of iPN hydrogels was successful upon subcutaneous injection.
Regenerative Therapy, 2024 • January 1, 2024
This study elucidates the mechanism by which MSCs-EVs, enriched with miR-26b-5p, attenuate spinal cord injury (SCI) by targeting the KDM6A/NOX4 axis. The findings indicate that MSCs-EVs deliver miR-26...
KEY FINDING: MSCs-EVs alleviate motor dysfunction, inflammation, and oxidative stress in SCI rats, suggesting a therapeutic effect.
Regenerative Therapy, 2023 • November 5, 2023
This study investigates the therapeutic potential of dental pulp stem cells (DPSCs) modified to overexpress osteopontin (OPN), Insulin-like growth factor 1 (IGF-1), and ciliary-derived neurotrophic fa...
KEY FINDING: DPSC-OIC treatment could increase Basso-Mouse Scale (BMS) scores, improve Magnetic Resonance Imaging (MRI) manifestation and promote bladder function recovery in SCI mice.